AR095691A1 - FORMULACIÓN DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca), PROCEDIMIENTO, USO - Google Patents
FORMULACIÓN DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca), PROCEDIMIENTO, USOInfo
- Publication number
- AR095691A1 AR095691A1 ARP140101303A ARP140101303A AR095691A1 AR 095691 A1 AR095691 A1 AR 095691A1 AR P140101303 A ARP140101303 A AR P140101303A AR P140101303 A ARP140101303 A AR P140101303A AR 095691 A1 AR095691 A1 AR 095691A1
- Authority
- AR
- Argentina
- Prior art keywords
- methylethydropholate
- amorfo
- mthf
- formulation
- procedure
- Prior art date
Links
- VWBBRFHSPXRJQD-ZEDZUCNESA-L calcium-L-methylfolate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 VWBBRFHSPXRJQD-ZEDZUCNESA-L 0.000 title 1
- 235000005934 calcium-L-methylfolate Nutrition 0.000 title 1
- 239000011681 calcium-L-methylfolate Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 abstract 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract 1
- 239000012752 auxiliary agent Substances 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 abstract 1
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 abstract 1
- 229960004845 drospirenone Drugs 0.000 abstract 1
- 229960002568 ethinylestradiol Drugs 0.000 abstract 1
- 229960003208 levomefolic acid Drugs 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Forma farmacéutica que comprende L-5-metilfolato de calcio amorfo y cisteína como agente estabilizante y opcionalmente, agentes auxiliares adicionales. Reivindicación 5: Forma farmacéutica según una cualquiera de las reivindicaciones 1 a 3, que comprende además: de 10 a 50 mg de etinil estradiol, de 0,5 a 5 mg de drospirenona.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13382106.6A EP2781214A1 (en) | 2013-03-22 | 2013-03-22 | Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca) |
Publications (1)
Publication Number | Publication Date |
---|---|
AR095691A1 true AR095691A1 (es) | 2015-11-04 |
Family
ID=48045387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140101303A AR095691A1 (es) | 2013-03-22 | 2014-03-20 | FORMULACIÓN DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca), PROCEDIMIENTO, USO |
Country Status (10)
Country | Link |
---|---|
US (1) | US20160045440A1 (es) |
EP (2) | EP2781214A1 (es) |
AR (1) | AR095691A1 (es) |
BR (1) | BR112015024351A2 (es) |
CA (1) | CA2907746A1 (es) |
CL (1) | CL2015002817A1 (es) |
MX (1) | MX2015013535A (es) |
PE (1) | PE20151891A1 (es) |
RU (1) | RU2015139983A (es) |
WO (1) | WO2014146975A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3190112A4 (en) * | 2014-09-04 | 2017-09-13 | Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd. | Composition of (6s)-5-methyl tetrahydrofolic acid or salt thereof as well as preparation therefor and application thereof |
WO2016123076A1 (en) * | 2015-01-27 | 2016-08-04 | La Vita Compounding Pharmacy | Stable 5-methyltrahydrofolate formulations to moderate methylenetetrahydrofolate reductase associated polymorphisms |
CA3036511A1 (en) * | 2016-09-12 | 2018-03-15 | Steven Hoffman | Compositions for treating dementia |
CN109164182B (zh) * | 2018-09-19 | 2021-06-11 | 无锡紫杉药业有限公司 | 一种对l-四氢叶酸对甲苯磺酸盐(6s)光学纯度的分析检测方法 |
EP3666260A1 (en) | 2018-12-13 | 2020-06-17 | Laboratorios Leon Farma SA | Ethinyl estradiol-beta-cyclodextrin complex and process for preparing thereof |
IL298209A (en) | 2020-05-15 | 2023-01-01 | Alfasigma Spa | A preparation containing methylfolate |
CN113403355B (zh) * | 2021-06-17 | 2022-05-31 | 山东大学 | 一种生物法生产l-5-甲基四氢叶酸的方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223500A (en) * | 1977-02-22 | 1993-06-29 | Bioresearch S.P.A. | Stable pharmaceutical composition of alkaline or alkaline earth 5-methyl tetrahydrofolate |
US5124452A (en) * | 1978-07-10 | 1992-06-23 | Bioresearch S.P.A. | Process for producing d,1-5-methyltetrahydrofolic acid and its salts |
CH693905A5 (de) | 1999-04-15 | 2004-04-15 | Eprova Ag | Stabile kristalline Salze von 5-Methyltetrahydrofolsäure. |
UY29527A1 (es) | 2005-05-13 | 2006-12-29 | Schering Ag | Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato. |
CN101489563A (zh) * | 2006-07-06 | 2009-07-22 | 拜耳先灵医药股份有限公司 | 用于避孕和预防先天性畸形风险的药物制剂 |
CH698729B1 (de) | 2007-05-30 | 2009-10-15 | Cerbios Pharma Sa | Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure. |
CN102813656B (zh) * | 2012-09-13 | 2014-05-07 | 广东岭南制药有限公司 | 5-甲基四氢叶酸或其盐的稳定药物组合物 |
-
2013
- 2013-03-22 EP EP13382106.6A patent/EP2781214A1/en not_active Withdrawn
-
2014
- 2014-03-13 CA CA2907746A patent/CA2907746A1/en not_active Abandoned
- 2014-03-13 BR BR112015024351A patent/BR112015024351A2/pt not_active IP Right Cessation
- 2014-03-13 RU RU2015139983A patent/RU2015139983A/ru unknown
- 2014-03-13 WO PCT/EP2014/055026 patent/WO2014146975A1/en active Application Filing
- 2014-03-13 EP EP14709708.3A patent/EP2976066A1/en not_active Withdrawn
- 2014-03-13 PE PE2015002018A patent/PE20151891A1/es not_active Application Discontinuation
- 2014-03-13 MX MX2015013535A patent/MX2015013535A/es unknown
- 2014-03-13 US US14/778,818 patent/US20160045440A1/en not_active Abandoned
- 2014-03-20 AR ARP140101303A patent/AR095691A1/es unknown
-
2015
- 2015-09-21 CL CL2015002817A patent/CL2015002817A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20160045440A1 (en) | 2016-02-18 |
CL2015002817A1 (es) | 2016-03-11 |
BR112015024351A2 (pt) | 2017-07-18 |
MX2015013535A (es) | 2016-05-31 |
RU2015139983A (ru) | 2017-04-25 |
CA2907746A1 (en) | 2014-09-25 |
PE20151891A1 (es) | 2015-12-20 |
EP2781214A1 (en) | 2014-09-24 |
EP2976066A1 (en) | 2016-01-27 |
WO2014146975A1 (en) | 2014-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR095691A1 (es) | FORMULACIÓN DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca), PROCEDIMIENTO, USO | |
NI201700011A (es) | 2-(morfolin-4-il)-1,7-naftiridinas. | |
CL2017002792A1 (es) | Derivados de ciclohexano sustituido con amido | |
CL2016001547A1 (es) | Composiciones para el cuidado oral | |
PE20151778A1 (es) | Formulacion combinada de dos compuestos antivirales | |
MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
CL2015003072A1 (es) | Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas. | |
BR112017028048A2 (pt) | drospirenona como o único ingrediente contraceptivo para uso | |
CL2016000009A1 (es) | Tratamiento de rosacea papulopustular con ivermectina. | |
CL2015002433A1 (es) | Imidazopiridazinas sustituidas | |
DOP2016000007A (es) | Pirazolpiridinas sustituidas | |
UY35848A (es) | Tienopirimidinas | |
CL2016002879A1 (es) | Composiciones farmacéuticas para tratar enfermedades infecciosas | |
CL2017003437A1 (es) | Formulación solida oral que contiene irinotecán y método de preparación de la misma | |
CO2017006958A2 (es) | Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para la preparación y uso de los mismos | |
CL2015001748A1 (es) | Formulaciones antiparasitarias transdermicas | |
CL2019002480A1 (es) | Derivados de pirazol como inhibidores de bromodominio. | |
MX2016005092A (es) | Composiciones farmaceuticas de estradiol insertadas en la vagina y metodos. | |
CL2019000174A1 (es) | Composición vaginal que comprende una combinación de estrógeno y vitamina d. | |
UY37444A (es) | Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y su uso | |
CL2015003460A1 (es) | Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica | |
CL2015003014A1 (es) | Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas. | |
PE20151432A1 (es) | Formulaciones de lorazepam de liberacion sostenida | |
EP2987492A4 (en) | USE OF 7A- [9- (4,4,5,5,5-PENTAFLUOR-PENTYL-SULFINYL-) NONYL] ESTRA-1,3,5 (10) -TRIEN-3,17B-DIOL AND DERIVATIVES THEREOF | |
CO7131364A2 (es) | Anillo vaginal que comprende meloxicam y un agente modulador de la liberación del principio activo, útil como anticonceptivo de uso continuo en mujeres |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |